HC Wainwright started coverage on shares of Proteon Therapeutics Inc. (NASDAQ:PRTO) in a research report released on Thursday. The brokerage issued a buy rating and a $18.00 price target on the biopharmaceutical company’s stock.
Separately, Zacks Investment Research raised Proteon Therapeutics from a sell rating to a hold rating in a research note on Wednesday, July 20th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $20.80.
Proteon Therapeutics (NASDAQ:PRTO) opened at 9.0301 on Thursday. Proteon Therapeutics has a 1-year low of $4.90 and a 1-year high of $17.76. The firm’s 50-day moving average is $9.22 and its 200 day moving average is $8.01. The stock’s market capitalization is $149.74 million.
Proteon Therapeutics (NASDAQ:PRTO) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. Equities analysts anticipate that Proteon Therapeutics will post ($1.85) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Paloma Partners Management Co acquired a new position in shares of Proteon Therapeutics during the second quarter valued at $234,000. Deerfield Management Co. increased its position in Proteon Therapeutics by 22.7% in the second quarter. Deerfield Management Co. now owns 1,552,031 shares of the biopharmaceutical company’s stock valued at $12,463,000 after buying an additional 286,688 shares in the last quarter. Bridgeway Capital Management Inc. increased its position in Proteon Therapeutics by 211.2% in the second quarter. Bridgeway Capital Management Inc. now owns 36,835 shares of the biopharmaceutical company’s stock valued at $296,000 after buying an additional 25,000 shares in the last quarter. TFS Capital LLC purchased a new position in Proteon Therapeutics during the second quarter valued at approximately $206,000. Finally, Geode Capital Management LLC increased its position in Proteon Therapeutics by 6.3% in the first quarter. Geode Capital Management LLC now owns 45,412 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 2,685 shares in the last quarter. 51.54% of the stock is owned by institutional investors and hedge funds.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.